- Home
- GNFT vs CDXS Comparison
GNFT vs CDXS Comparison
Compare GNFT & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNFT
- CDXS
- Stock Information
- Founded
- GNFT 1999
- CDXS 2002
- Country
- GNFT France
- CDXS United States
- Employees
- GNFT N/A
- CDXS N/A
- Industry
- GNFT Biotechnology: Biological Products (No Diagnostic Substances)
- CDXS Major Chemicals
- Sector
- GNFT Health Care
- CDXS Industrials
- Exchange
- GNFT Nasdaq
- CDXS Nasdaq
- Market Cap
- GNFT 296.4M
- CDXS 332.0M
- IPO Year
- GNFT 2019
- CDXS 2010
- Fundamental
- Price
- GNFT $3.79
- CDXS $5.67
- Analyst Decision
- GNFT Strong Buy
- CDXS Buy
- Analyst Count
- GNFT 1
- CDXS 2
- Target Price
- GNFT $13.00
- CDXS $11.00
- AVG Volume (30 Days)
- GNFT 6.6K
- CDXS 691.3K
- Earning Date
- GNFT 09-19-2024
- CDXS 10-31-2024
- Dividend Yield
- GNFT N/A
- CDXS N/A
- EPS Growth
- GNFT N/A
- CDXS N/A
- EPS
- GNFT 0.47
- CDXS N/A
- Revenue
- GNFT $86,225,222.00
- CDXS $64,446,000.00
- Revenue This Year
- GNFT $155.44
- CDXS N/A
- Revenue Next Year
- GNFT N/A
- CDXS $2.02
- P/E Ratio
- GNFT $7.85
- CDXS N/A
- Revenue Growth
- GNFT 175.45
- CDXS N/A
- 52 Week Low
- GNFT $3.31
- CDXS $2.53
- 52 Week High
- GNFT $6.42
- CDXS $6.08
- Technical
- Relative Strength Index (RSI)
- GNFT 26.93
- CDXS 71.90
- Support Level
- GNFT $3.63
- CDXS $5.42
- Resistance Level
- GNFT $3.85
- CDXS $6.01
- Average True Range (ATR)
- GNFT 0.12
- CDXS 0.33
- MACD
- GNFT 0.01
- CDXS 0.03
- Stochastic Oscillator
- GNFT 11.88
- CDXS 69.68
About GNFT GENFIT S.A.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of innovative medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.
About CDXS Codexis Inc.
Codexis Inc is involved in the business of providing enzyme optimization services, commercialization of proteins, and developing biocatalyst products, leveraging its proprietary CodeEvolver directed evolution technology platform. The firm's products and services include Biocatalysts and Enzymes. The company generates majority of its revenue through product sales and also licenses its technology platform CodeEvolver to pharmaceutical companies enabling them to use this technology, in-house, to engineer enzymes for their own businesses. Geographically, it derives revenue from the United States, Ireland, Switzerland, China and other markets.